A Phase 2 Study of the Efficacy, Durability and Safety of Ampreloxetine (TD-9855), a Norepinephrine Reuptake Inhibitor, Given Once-daily to Treat Neurogenic Orthostatic Hypotension (nOH) in Subjects with Synucleinopathies
Objective: To assess the efficacy and durability using validated symptom questionnaire OHQ, and safety of ampreloxetine, given once-daily to treat neurogenic orthostatic hypotension (nOH) in…Influence of demographic characteristics in the efficacy response of Parkinson’s disease patients with motor fluctuations: post-hoc analysis from combined BIPARK-I and II.
Objective: To evaluate the impact of demographic characteristics in the efficacy response of levodopa-treated Parkinson’s Disease (PD) patients with motor fluctuations. Background: Opicapone (OPC), a…African American patients with Parkinson’s disease: A hospital-based study compared to Caucasian patients
Objective: To characterize the demographic, socioeconomic, clinical and healthcare features of African American (AA) patients with Parkinson’s disease (PD) compared to Caucasian PD patients in…Incidence of treatment-emergent adverse events in Parkinson’s disease patients according to baseline disease severity: post-hoc analysis from double-blind combined BIPARK-I and II data
Objective: To evaluate the incidence of treatment-emergent adverse events (TEAEs) in levodopa-treated Parkinson’s Disease (PD) patients with motor fluctuations and taking opicapone (OPC). Background: OPC…A Phase 2 Dose Escalation Study of Ampreloxetine (TD-9855), a Norepinephrine Reuptake Inhibitor, Given Once-Daily to Treat Neurogenic Orthostatic Hypotension (nOH) in Subjects with Synucleinopathies
Objective: To assess the acute effects of ampreloxetine on the pressor response, improvement of symptoms and safety in a daily, single, escalating doses. Background: nOH…Influence of motor fluctuations duration, levodopa dose and duration of use in efficacy responses of Parkinson’s disease patients: post-hoc analysis from combined BIPARK-I and II.
Objective: To evaluate the impact of motor fluctuations (MF) duration, levodopa dose and levodopa duration of use (LDU) in efficacy responses of levodopa-treated Parkinson’s Disease…Influence of controlled-release levodopa on quality of sleep and nocturnal movements
Objective: To evaluate the effects of controlled-released (CR) levodopa on quality of sleep and nocturnal movements as assessed with mobile health technology in patients with…A framework to facilitate competence in practice for Parkinson’s Disease Nurse Specialists in the United Kingdom
Objective: To determine if the current Parkinson's Disease Nurse Specialist (PDNS) competency framework 2nd Edition 2008 (1) for nurses working in the management of Parkinson's…Neurological improvement with WTX101 treatment in a Phase 2, multi-center, open label study in Wilson Disease
Objective: The objective of this study was to characterize neurological manifestations in Wilson Disease (WD) patients and describe specific neurological changes after 24 weeks’ treatment…Evaluating long-term effectiveness of carbidopa/levodopa enteral suspension in advanced Parkinson’s Disease patients: PROviDE study design and baseline characteristics
Objective: To evaluate the real-world long-term effectiveness of CLES on advanced PD patients and their caregivers. Background: Carbidopa/levodopa enteral suspension (CLES) was approved in USA…
- « Previous Page
- 1
- …
- 24
- 25
- 26
- 27
- 28
- …
- 34
- Next Page »